Judith Lindner - Concepedia

Author

Judith Lindner

Charité - Universitätsmedizin Berlin ORCID

Also Known As

J LINDNER, J Lindner, J. Lindner, J.L. Lindner, Judith L Lindner, Judith L. Lindner, Judith Lea Lindner, Judith Lindner, Lindner, Judith Lea

Publications

825

Citations

H-Index

Concepts

All Affiliations

Charité - Universitätsmedizin Berlin Luisenkrankenhaus Clinical Research Center for Hair and Skin Science German Breast group Deutschen Konsortium für Translationale Krebsforschung

About

Judith Lindner is an author at Charité - Universitätsmedizin Berlin specializing in radiation oncology, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	233
2	Pathology	4	4	137
3	Biochemistry	1	1	96
4	Cell Biology	1	1	13
5	Obstetrics	1	1	12

Judith Lindner

Publications

807

Citations

H-Index

Page 1

	Year	Citations
<i>PIK3CA</i> Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti–Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer Sibylle Loibl, Gϋnter von Minckwitz, Andreas Schneeweiß, Journal of Clinical Oncology	2014	247
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma Silvia Darb‐Esfahani, Catarina Alisa Kunze, Hagen Kulbe, Oncotarget	2015	236
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy Judith Lindner, Sibylle Loibl, Carsten Denkert, Annals of Oncology Secreted Protein AcidicBreast OncologyBiochemistryMedicineBreast Cancer	2014	96
SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study M. Sinn, B.V. Sinn, Jana K. Striefler, Annals of Oncology Surgical OncologyPancreatic CancerGastrointestinal OncologyMedicinePathology	2014	75
Clinical relevance and concordance of HER2 status in local and central testing—an analysis of 1581 HER2-positive breast carcinomas over 12 years Berit M. Pfitzner, Bianca Lederer, Judith Lindner, Modern Pathology Her2 StatusBreast OncologyMedicineClinical RelevancePathology	2017	37
Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: a cohort study Varvara Kanti, Rima Nuwayhid, Judith Lindner, British Journal of Dermatology	2013	34
Hair shaft abnormalities after chemotherapy and tamoxifen therapy in patients with breast cancer evaluated by optical coherence tomography Judith Lindner, Kathrin Hillmann, Ulrike Blume‐Peytavi, British Journal of Dermatology	2012	22
Effectiveness of Immune Checkpoint Inhibition vs Chemotherapy in Combination With Radiation Therapy Among Patients With Non–Small Cell Lung Cancer and Brain Metastasis Undergoing Neurosurgical Resection David Wasilewski, Josefine Radke, Ran Xu, JAMA Network Open	2022	22
Abstract S4-06: PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer – Prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies Sibylle Loibl, Carsten Denkert, Andreas Schneeweis, Cancer Research Breast OncologyPhosphatidylinositol 3-KinasePathologyTumor BiologyOncology	2013	13
Evaluation of trichodynia (hair pain) during chemotherapy or tamoxifen treatment in breast cancer patients Varvara Kanti, Rima Nuwayhid, Judith Lindner, Journal of the European Academy of Dermatology and Venereology	2015	13

Page 1